Pharmaceutical formulations for the treatment of migraine
US12310953B2 · kind B2 · utility
1Cited by
37References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2024 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Sep 19, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.